DrugCendR to Present Immuno-Oncology Data at the annual AACR meeting

Main image Main image

Cend Therapeutics In The News

DrugCendR to Present Immuno-Oncology Data at the annual AACR meeting
March 25, 2019

DrugCendR Inc. COO Harri Jarvelainen will present a poster at the annual American Association for Cancer Research (AACR) meeting (March 29-April 4, 2019, Atlanta, GA). The poster is entitled “Co-administration of the iRGD tumor-penetrating peptide improves the tumor immunostimulatory effects of low-dose IL-2”.